Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 15/20 | 0.68 |
| ▸ | METAP2 | P50579 | 1/20 | 0.48 |
| ▸ | F9 | P00740 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5651066 | 0.93 | FLT3 (0.61) | FLT3METAP2F9 | |
| SCHEMBL5650968 | 0.91 | FLT3 (0.70) | FLT3METAP2F9HDAC3HDAC7 | |
| SCHEMBL5652462 | 0.89 | FLT3 (0.68) | FLT3F9HDAC3HDAC7HDAC10 | |
| SCHEMBL5650803 | 0.88 | FLT3 (0.65) | FLT3METAP2F9HDAC6 | |
| SCHEMBL5651747 | 0.88 | FLT3 (0.53) | FLT3METAP2F9HDAC3HDAC7 | |
| SCHEMBL5650106 | 0.87 | FLT3 (0.63) | FLT3F9 | |
| SCHEMBL5653300 | 0.86 | FLT3 (0.72) | FLT3F9 | |
| SCHEMBL5651375 | 0.85 | FLT3 (0.50) | FLT3METAP2 | |
| SCHEMBL5649758 | 0.84 | FLT3 (0.69) | FLT3F9 | |
| SCHEMBL5649698 | 0.84 | FLT3 (0.50) | FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | FLT3 1968/4885METAP2 3311/4885F9 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.